Eric Roos

Generic and Biosimilar Medicines of Southern Africa (GBMSA),
formerly known as the National Association of Pharmaceutical Manufacturers
(NAPM), has appointed Erik Roos, CEO of Pharma Dynamics as Vice Chairperson to
support the existing Chairperson, Lorraine Keyser, CEO of Dr Reddy’s, as of
June 2018.

Over the past 40+ years the association has played a
critical role in ensuring that the pharmaceutical sector remains a key driver
of economic growth, development and transformation in the country, while
continuing to champion affordable and accessible healthcare through the
promotion of generic and biosimilar medicines.

As Chairperson of GBMSA, Keyser will be responsible for
overseeing the committee, while Vice Chairperson, Erik Roos will support the
Chairperson in representing the association on the Pharmaceutical Task Group
(PTG), which primarily deals with issues relating to legislation and pricing.

As an industry veteran, Roos brings a wealth of experience
to the position and says he looks forward to the challenge of working with and
representing the GBMSA member companies to shape a more favourable healthcare

His two-year tenure in office will involve working alongside
SAHPRA to ensure the speedy approval of medicine registrations, while
evaluating the impact that the Health Charter and NHI will have on both state
and private healthcare reform in SA.

“We have ambitious plans ahead and I intend on working with
all stakeholders to achieve a common goal.”

“I am also encouraged by the recently announced changes to
the country’s Intellectual Property Policy, which will curb uncompetitive
practices such as patent evergreening, which has hampered consumers’ access to
more affordable medication for far too long.”

“The introduction of a substantive search and patent
examination office will do away with unscrupulous companies that use loopholes
to extend patents after the 20-year exclusivity period for their own financial
gain. This move by government will see a flood of generic medicines enter the
market, which will be manufactured and sold at a fraction of the price of
original medicines, benefiting consumers and funders.”

“Both generic and biosimilar medication will continue to
play a pivotal role in curbing healthcare expenditure well into the future,”
says Roos.